Selskabets formål er at drive kommercielle aktiviteter inden for biotek, herunder udvikling af mikrober eller planter gennem en patenteret udviklingsteknologi samt enhver dertil knyttet aktivitet.
| Year | Revenue | Profit/Loss | Total Assets | Equity | Employees | Report |
|---|---|---|---|---|---|---|
| 2024 | 18 mio. | -26.9 mio. | 234.5 mio. | 185.2 mio. | 25 | |
CVR: 43713523
Hanne Vibeke Weywardt left the board
Carsten Sparre Conrad joined the board
Companies in the same industry and area
CVR 37598194
CVR 46133684
CVR 43917897
CVR 45599124
CVR 45831906
Compared to 992 companies in Forskning og eksperimentel udvikling inden for naturvidenskab og teknik
Comparison is based on industry median values
TRAITOMIC A/S is currently facing financial challenges, as evidenced by its declining profitability and increasing losses over the past two years. In 2024, the company reported a revenue of 18,027,000 DKK but incurred a significant loss of 26,917,000 DKK, following a revenue of 23,202,000 DKK and a loss of 20,231,000 DKK in 2023. Despite these losses, TRAITOMIC maintains a robust equity position of 185,150,000 DKK, indicating a strong capital base that could support future growth. However, the negative profit margins raise concerns about its operational efficiency and sustainability within the competitive research and development sector.
AI-generated summary
companydata.dk